Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Nasopharyngitis (Common Cold) Overview | 6 | 1 |
| Therapeutics Development | 7 | 2 |
| Pipeline Products for Nasopharyngitis (Common Cold) Overview | 7 | 1 |
| Pipeline Products for Nasopharyngitis (Common Cold) Comparative Analysis | 8 | 1 |
| Nasopharyngitis (Common Cold) Therapeutics under Development by Companies | 9 | 1 |
| Nasopharyngitis (Common Cold) Therapeutics under Investigation by Universities/Institutes | 10 | 1 |
| Nasopharyngitis (Common Cold) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Nasopharyngitis (Common Cold) Products under Development by Companies | 13 | 1 |
| Nasopharyngitis (Common Cold) Products under Investigation by Universities/Institutes | 14 | 1 |
| Nasopharyngitis (Common Cold) Companies Involved in Therapeutics Development | 15 | 4 |
| Charleston Laboratories, Inc. | 15 | 1 |
| Cocrystal Pharma, Inc. | 16 | 1 |
| Orbis Biosciences Inc | 17 | 1 |
| Vernalis Plc | 18 | 1 |
| Nasopharyngitis (Common Cold) Therapeutics Assessment | 19 | 10 |
| Assessment by Monotherapy Products | 19 | 1 |
| Assessment by Combination Products | 20 | 1 |
| Assessment by Target | 21 | 2 |
| Assessment by Mechanism of Action | 23 | 2 |
| Assessment by Route of Administration | 25 | 2 |
| Assessment by Molecule Type | 27 | 2 |
| Drug Profiles | 29 | 10 |
| (levocetirizine dihydrochloride + montelukast sodium) Drug Profile | 29 | 1 |
| Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders Drug Profile | 30 | 1 |
| CCP-05 Drug Profile | 31 | 1 |
| CCP-06 Drug Profile | 32 | 1 |
| CCP-07 Drug Profile | 33 | 1 |
| CCP-08 Drug Profile | 34 | 1 |
| CLAT-313 Drug Profile | 35 | 1 |
| guaifenesin ER Drug Profile | 36 | 1 |
| Small Molecule to Inhibit MAPK13 for Asthma and Cold Drug Profile | 37 | 1 |
| Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold Drug Profile | 38 | 1 |
| Nasopharyngitis (Common Cold) Dormant Projects | 39 | 1 |
| Nasopharyngitis (Common Cold) Discontinued Products | 40 | 1 |
| Nasopharyngitis (Common Cold) Product Development Milestones | 41 | 3 |
| Featured News &Press Releases | 41 | 1 |
| Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study | 41 | 1 |
| Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study | 41 | 1 |
| Dec 21, 2015: Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study | 41 | 1 |
| Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine | 42 | 1 |
| Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing | 42 | 1 |
| Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept | 43 | 1 |
| Appendix | 44 | 2 |
| Methodology | 44 | 1 |
| Coverage | 44 | 1 |
| Secondary Research | 44 | 1 |
| Primary Research | 44 | 1 |
| Expert Panel Validation | 44 | 1 |
| Contact Us | 44 | 1 |
| Disclaimer | 45 | 1 |